अन्य औषधि, खाना र जडीबुटी उत्पादनले Brivaracetam को काम बदल्न सक्छन्। यस पृष्ठका सबै कुरा Brivaracetam कै FDA-स्वीकृत लेबलबाट आएका हुन् — मुख्य गाइडकै स्रोतबाट।
लेबलले जसरी समूह बनाएको छ, त्यसरी नै राखिएको छ। प्रत्येक नाम त्यस औषधिको NepalDoc गाइडसँग जोडिन्छ; लेबलले औषधिको नाम नभई वर्ग मात्र भनेको ठाउँमा लेबलकै शब्द उद्धृत गरिएको छ।
Rifampin Co-administration with rifampin decreases brivaracetam plasma concentrations likely because of CYP2C19 induction . Prescribers should increase the brivaracetam dose by up to 100% (i.e., double the dosage) in patients while receiving concomitant treatment with rifampin .Carbamazepine Co-administration with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine. Though available data did not reveal any safety concerns, if tolerability issues arise when co-administered, carbamazepine dose reduction should be considered .Brivaracetam can increase plasma concentrations of phenytoin, phenytoin levels should be monitored in patients when concomitant brivaracetam is added to or discontinued from ongoing phenytoin therapy .Levetiracetam Brivaracetam provided no added therapeutic benefit to levetiracetam when the two drugs were co-administered .Brivaracetam को लेबलले ४ औषधिको नाम लिएको छ, जुन NepalDoc मा पनि छन्।
यहाँ नाम भएका यी औषधिका आफ्नै अन्तरक्रिया पृष्ठ पनि छन्:
Rifampin: Because of decreased concentrations, increasing brivaracetam oral solution dosage in patients on concomitant rifampin is recommended. Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant brivaracetam oral solution. Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant brivaracetam. Levetiracetam: Brivaracetam had no added therapeutic benefit when co- administered with levetiracetam.
7.1 Rifampin Co-administration with rifampin decreases brivaracetam plasma concentrations likely because of CYP2C19 induction . Prescribers should increase the brivaracetam dose by up to 100% (i.e., double the dosage) in patients while receiving concomitant treatment with rifampin .
7.2 Carbamazepine Co-administration with carbamazepine may increase exposure to carbamazepine-epoxide, the active metabolite of carbamazepine. Though available data did not reveal any safety concerns, if tolerability issues arise when co-administered, carbamazepine dose reduction should be considered .
7.3 Phenytoin Because brivaracetam can increase plasma concentrations of phenytoin, phenytoin levels should be monitored in patients when concomitant brivaracetam is added to or discontinued from ongoing phenytoin therapy .
7.4 Levetiracetam Brivaracetam provided no added therapeutic benefit to levetiracetam when the two drugs were co-administered .
Brivaracetam गाइड · सबै अन्तरक्रिया पृष्ठहरू · औषधि A–Z
यो पृष्ठले Brivaracetam को FDA-स्वीकृत लेबलको सारांश जानकारीका लागि दिन्छ — यो चिकित्सकीय सल्लाह होइन। तपाईंले लिने हरेक औषधि, सप्लिमेन्ट र जडीबुटी उत्पादनबारे आफ्नो डाक्टर वा फार्मासिस्टलाई सधैं भन्नुहोस्।
यो पृष्ठ सामान्य जानकारीका लागि मात्र हो, चिकित्सकीय सल्लाह होइन। औषधि प्रयोग गर्नुअघि डाक्टर वा फार्मासिस्टसँग सल्लाह लिनुहोस्। विवरण माथि उल्लेखित स्रोतहरूबाट आएको हो र परिवर्तन हुन सक्छ। सूचीमा हुनुले कुनै फार्मेसीमा औषधि उपलब्ध छ भन्ने ग्यारेन्टी दिँदैन।
नेपालडकका सबै खण्ड, एकै ठाउँमा।
विशेषज्ञताअनुसार नेपालभरका डाक्टर खोज्नुहोस्।